Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Research

MMP-9 and Its Regulators TIMP-1 and EMMPRIN in Patients with Acute ST-Elevation Myocardial Infarction: A NORDISTEMI Substudy

Opstad T.B.a-d · Seljeflot I.a-d · Bøhmer E.e · Arnesen H.a,c,d · Halvorsen S.b-d

Author affiliations

aCenter for Clinical Heart Research and bDepartment of Cardiology, Oslo University Hospital Ullevål, cCenter for Heart Failure Research, Oslo University Hospital, and dFaculty of Medicine, University of Oslo, Oslo, and eInnlandet Hospital Trust, Lillehammer, Norway

Related Articles for ""

Cardiology 2018;139:17-24

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: July 13, 2017
Accepted: September 20, 2017
Published online: November 16, 2017
Issue release date: January 2018

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD

Abstract

Objectives: The extracellular matrix is involved in wound repair after acute myocardial infarction (AMI). We investigated whether matrix metalloproteinase (MMP)-9, tissue inhibitor of metalloproteinases (TIMP)-1, and the MMP inducer (EMMPRIN) are associated with infarct size, left ventricular function, and clinical outcome in ST-elevation-MI (STEMI). Methods: In 243 STEMI patients, circulating EMMPRIN, MMP-9, and TIMP-1 were analyzed 3 days and 3 months post-AMI. Infarct size and left ventricular ejection fraction were assessed by single-photon emission computed tomography (SPECT) (n = 230/226) and MRI (n = 111/167) at 3 months. Results: EMMPRIN, MMP-9, and TIMP-1 levels and the MMP-9/TIMP-1 ratio declined from day 3 to 3 months (p < 0.001, all). TIMP-1 levels at day 3 correlated significantly with SPECT- and MRI-based infarct size, troponin T (p < 0.04, all), and amino-terminal pro-B-type natriuretic peptide (NT-proBNP; p < 0.001). The upper quartile of day 3 TIMP-1 levels showed an adjusted odds ratio of 5.0 (95% confidence interval 1.2-20.6) for having a large infarct size. An insignificant relationship between MMP-9 and clinical events within 1 year (death, AMI, or stroke) (n = 15) was observed, probably due to the lack of statistical power. Conclusion: The decline in EMMPRIN, MMP-9, and TIMP-1 3 months after acute STEMI is probably due to initial acute-phase processes. The associations between TIMP-1, infarct size, and NT-proBNP indicate a role for TIMP-1 in cardiac remodeling.

© 2017 S. Karger AG, Basel


References

  1. Heggtveit HA: Morphological alterations in the ischaemic heart. Cardiology 1971;56:284-290.
    External Resources
  2. Pfeffer MA, Braunwald E: Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-1172.
  3. Frangogiannis NG, Smith CW, Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
  4. Vanhoutte D, Schellings M, Pinto Y, Heymans S: Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006;69:604-613.
  5. Kawakami R, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Nakagawa Y, Nakanishi M, Tanimoto K, Usami S, Yasuno S, Kinoshita H, Chusho H, Tamura N, Ogawa Y, Nakao K: Overexpression of brain natriuretic peptide facilitates neutrophil infiltration and cardiac matrix metalloproteinase-9 expression after acute myocardial infarction. Circulation 2004;110:3306-3312.
  6. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, Lee RT: Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 2000;106:55-62.
  7. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
  8. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998;32:368-372.
  9. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000;1477:267-283.
  10. Lambert E, Dassé E, Haye B, Petitfrère E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
  11. Lovelock JD, Baker AH, Gao F, Dong JF, Bergeron AL, McPheat W, Sivasubramanian N, Mann DL: Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005;288:H461-H468.
  12. Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, Kim HS, Cho SH, Song KS, Sangiorgi G: Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005;180:37-44.
  13. Schmidt R, Bültmann A, Ungerer M, Joghetaei N, Bülbül O, Thieme S, Chavakis T, Toole BP, Gawaz M, Schömig A, May AE: Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006;113:834-841.
  14. Reddy VS, Prabhu SD, Mummidi S, Valente AJ, Venkatesan B, Shanmugam P, Delafontaine P, Chandrasekar B: Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-κB activation. Am J Physiol Heart Circ Physiol 2010;299:H1242-H1254.
  15. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, Squire IB: Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J 2008;29:2116-2124.
  16. Chu JW, Jones GT, Tarr GP, Phillips LV, Wilkins GT, van Rij AM, Williams MJ: Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. Int J Cardiol 2013;167:1242-1246.
  17. Furenes EB, Opstad TB, Solheim S, Lunde K, Arnesen H, Seljeflot I: The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction. Mediators Inflamm 2014;2014:385901.
  18. Su Z, Lin R, Chen Y, Shu X, Zhang H, Nie R, Wang J, Xie S: Knockdown of EMMPRIN improves adverse remodeling mediated by IL-18 in the post-infarcted heart. Am J Transl Res 2015;7:1908-1916.
    External Resources
  19. Bøhmer E, Arnesen H, Abdelnoor M, Mangschau A, Hoffmann P, Halvorsen S: The Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction (NORDISTEMI). Scand Cardiovasc J 2007;41:32-38.
  20. Bøhmer E, Hoffmann P, Abdelnoor M, Arnesen H, Halvorsen S: Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (Norwegian Study on District Treatment of ST-Elevation Myocardial Infarction). J Am Coll Cardiol 2010;55:102-110.
  21. Bøhmer E, Hoffmann P, Abdelnoor M, Seljeflot I, Halvorsen S: Troponin T concentration 3 days after acute ST-elevation myocardial infarction predicts infarct size and cardiac function at 3 months. Cardiology 2009;113:207-212.
  22. Mistry N, Bøhmer E, Hoffmann P, Müller C, Bjørnerheim R, Kjeldsen SE, Halvorsen S: Left ventricular function in acute myocardial infarction treated with thrombolysis followed by early versus late invasive strategy. Am Heart J 2010;160:73-79.
  23. Halvorsen S, Seljeflot I, Weiss T, Bøhmer E, Arnesen H: Inflammatory and thrombotic markers in patients with ST-elevation myocardial infarction treated with thrombolysis and early PCI: a NORDISTEMI substudy. Thromb Res 2012;130:495-500.
  24. Fertin M, Dubois E, Belliard A, Amouyel P, Pinet F, Bauters C: Usefulness of circulating biomarkers for the prediction of left ventricular remodeling after myocardial infarction. Am J Cardiol 2012;110:277-283.
  25. Koenig W, Khuseyinova N: Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27:15-26.
  26. Wang B, Xu SS, Jiang JJ, Lu XB, Xue YS, Wang JC, Mi YF, Zhu M, Ge WL, Tang LJ: Expression of extracellular matrix metalloproteinase inducer in the unstable plaque of patients with acute coronary syndrome (in Chinese). Zhonghua Xin Xue Guan Bing Za Zhi 2012;40:416-420.
    External Resources
  27. Radosinska J, Barancik M, Vrbjar N: Heart failure and role of circulating MMP-2 and MMP-9. Panminerva Med 2017;59:241-253.
  28. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L: Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003;107:1579-1585.
  29. Wang W, Song X, Chen Y, Yuan F, Xu F, Zhang M, Tan K, Yang X, Yu X, Lv S: The long-term influence of tissue inhibitor of matrix metalloproteinase-1 in patients with mild to moderate coronary artery lesions in a Chinese population: a 7-year follow-up study. Cardiology 2015;132:151-158.
  30. Opstad TB, Arnesen H, Pettersen AA, Seljeflot I: The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease. PLoS One 2014;9:e106816.
  31. Su Z, Lin R, Chen Y, Shu X, Zhang H, Nie R, Wang J, Xie S: Knockdown of EMMPRIN improves adverse remodeling mediated by IL-18 in the post-infarcted heart. Am J Transl Res 2015;7:1908-1916.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Research

Received: July 13, 2017
Accepted: September 20, 2017
Published online: November 16, 2017
Issue release date: January 2018

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 5

ISSN: 0008-6312 (Print)
eISSN: 1421-9751 (Online)

For additional information: https://www.karger.com/CRD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.